ARK stepped in while the stock was falling, across ARKK, ARKQ and ARKX. Below: the day's other trades and ARK's record against the index.

Generated from ARK's own holdings data.
On 16 Oct 2026, Cathie Wood's ARK bought an estimated $9.3M of Rocket Lab (RKLB) across ARKK and ARKQ and ARKX. The stock was 19% cheaper than a week earlier when the order went through.
When cash came into an ARK fund, every stock in it moves by the same percentage — about 20.3% that day. RKLB grew 9%, so this was a choice, not plumbing.
Over the last 30 days ARK has been a net buyer of Rocket Lab — $51.6M across 9 trades.
ARK made 14 real moves that day, once money flowing in and out of the funds is stripped out:
| Stock | Funds | Est. value |
|---|---|---|
| NTLA Intellia Therapeutics IncSold 3 days running | ARKG and ARKK | −$56.8M |
| RXRX Recursion Pharmaceuticals | ARKG and ARKK | +$17.6M |
| CRWV CoreWeave Inc | ARKK | +$13.0M |
| RKLB Rocket LabBought after a 19% drop this week | ARKK, ARKQ and ARKX | +$9.3M |
| AMZN Amazon.Com Inc | ARKK, ARKQ and ARKX | −$7.7M |
| SHOP Shopify Inc | ARKK | −$5.3M |
The 30-day picture: CoreWeave Inc ($85.0M), Nvidia Corp ($81.0M), Rocket Lab ($51.6M) have taken the most new money. Meanwhile the funds have been trimming Advanced Micro Devices ($126.3M), 10X Genomics Inc ($76.2M), Personalis Inc ($68.5M).
This year ARKK is behind the market — +11.4% against +14.1% for the S&P 500.
Over the past year the gap is wider: ARKK returned -4.0% against +17.3% for the S&P 500, 21 points apart.
That five-year gap — 110 points — mostly comes down to timing. Five years ago ARKK was trading close to its all-time high of Feb 2021. It then fell 81% to its low in Dec 2022, and it is still 44% below that peak today. Any comparison that starts near the top of that boom looks brutal.
| To date | 1 month | YTD | 1 year | 5 years |
|---|---|---|---|---|
| ARKK | +2.6% | +11.4% | -4.0% | -24.8% |
| S&P 500 (SPY) | +2.2% | +14.1% | +17.3% | +85.1% |
| Nasdaq-100 (QQQ) | +3.4% | +18.8% | +21.3% | +103.1% |
ETFpeek is an independent research tool and is not affiliated with ARK Invest or Cathie Wood. Figures are estimates from public fund data, shown for information only — not financial advice. Past performance does not indicate future results.